drugset / Trial / NCT04338126
Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A controlled trial of the drug tranexamic acid (TXA) in inpatients recently admitted to the hospital with the diagnosis of COVID19. It is hypothesized that TXA will reduce the infectivity and virulence of the virus.
Timeline
- Start
- 2021-09-30
- Primary completion
- 2021-12-15
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tranexamic Acid | Small molecule | 1 mg/kg | Oral |
| Subject | Tranexamic Acid | Small molecule | 1300 mg | Oral |